Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
sNDA
Sort By
Newest First
1 / 1
1 / 1
New Drug Application
AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax
AbbVie
PR-M07-18-NI-041
Jul 13, 2018
FDA
U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Astellas
PR-M03-18-NI-085
Mar 23, 2018
